The dose-response characteristics of dieldrin-mediated enhancement of liver tumour formation in CF-1 mice were analysed, using existing tumour data from chronic feeding studies at six levels of continuous exposure, involving a total of > 1500 animals. 
Introduction
A variety of xenobiotic compounds are known to induce characteristic changes in the livers of laboratory animals. These changes include: (i) liver enlargement, usually as a result of cell enlargement, polyploidisation or cell replication, (ii) induction of drugmetabolising enzymes, and (iii) proliferation of the smooth endoplasmic reticulum (1) (2) (3) (4) (5) (6) . Such changes are not usually accompanied by evidence of liver damage, and are reversible upon withdrawal and elimination of the compound (5, 6) . Consequently, this phenomenon is likely to be an adaptive response of liver to increased functional demands. However, chronic exposure of various strains of mice to microsoma] enzyme inducers, such as dieldrin, phenobarbitone, l,l,l-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT)* and hexachlorocyclohexane (HCH)-stereoisomers, may cause an increase in the incidence of liver tumours (7) (8) (9) (10) (11) (12) . Phenobarbitone, DDT, butylated hydroxytoluene (BHT) and a-HCH have also been shown to promote the formation of rat liver tumours from lesions previously initiated by hepatocarcinogens (13 -16) . By analogy, it has been suggested that microsomal enzyme inducers do not exert an intrinsically carcinogenic effect on mouse liver, but function by enhancing the effect of a pre-existing oncogenic factor, which may be of environmental
•Abbreviations: DDT, l,l,l-tricholoro-2,2-bis(p<hlorophenyl)ethane; HCH, hexachlorocyclohexane; BHT, butylated hydroxytoluene; 4-DAB, 4-dimethylajninoazobenzene.
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or genetic origin (5, 7) .
It is conceivable, in principle, that enhancers of carcinogenesis and intrinsically carcinogenic compounds exhibit different doseresponse characteristics. The dose-response characteristics of chemical carcinogens, in single-dose and chronic-exposure experiments, have been elucidated by Druckrey and his associates (17) (18) (19) (20) (21) (22) : D X T" = constant (1) where D = daily dose, T = the median tumour induction period, and n = an exponent, always > 1.
Thus, carcinogenic response is defined as the median time period required for a constant end-point of the carcinogenic process. Equation (1) describes a quantitative relationship between the median velocity of tumour formation (or tumour-associated death) and the dose level of the carcinogen (H.Druckrey, personal communication). Velocity is measured in units of reciprocal time and, accordingly, the most appropriate form of Druckrey's relationship is:
3) The dose-response characteristics of putative carcinogenesis enhancers have been studied with various model compounds, particularly with phenobarbital (23) (24) (25) (26) (27) , but no mathematical equivalent has emerged so far. We have recently reported a nonlinear relationship between the logarithm of daily dieldrin dose and the logarithm of the median liver tumour induction period in CF-1 mice (25) . This non-linearity contrasted wirn equation (1) . However, in the dieldrin study, the likelihood is that the velocityof tumour formation was determined by multiple factors, i.e., by combination of dieldrin dose and background factors (responsible for liver tumour development in untreated control CF-1 mice). In mathematical terms:
D o (4) where T x = median liver tumour induction period at a dieldrin dose level 6 X and D o = a background dose equivalent for liver tumour development in control CF-1 mice (when 6 X = 0), the velocity of which will be denoted as 1/T O . Accordingly, dieldrin dose related to the increase in the velocity of liver tumour formation only, i.e., to:
(1/T X ) -(1/T O ) (5) The aim of the present analysis was to elucidate a possible quantitative relationship between dose and response, as defined above.
Materials and methods
Details of animal experiments, liver pathology and statistical procedures have been reported previously (8, 9, 25) , but some important aspects are briefly reviewed. Treatment of CF-1 mice with dieldrin commenced at the age of 3 weeks. The animals were palpated weekly as from 16 weeks of treatment to detect the presence of intra-abdominal masses, and killed when the enlargement was considered to be detrimental to health. The treatment period up to that point was referred to as the liver tumour induction period. Liver tumours were classified as adenomas (nodular growths of solid cords of parenchymal cells) or carcinomas (papilloform and adenoid growth with cells proliferating in confluent sheets with necrosis, "Calculated on the basis of an average daily food intake of 100 g/kg bodyweight. ''Numbers in parentheses indicate 95% confidence intervals. c Carcinoma data considered too scant to warrant analysis.
Sixteen animals in this treatment group died from acute intoxication within the first 13 weeks of treatment. increased mitosis, and sometimes associated metastases to the lungs). No significant sex difference in the tumourigenic response of liver to dieldrin could be detected (25) , and tumour data for males and females within groups were combined. Details of statistical procedures have been described previously (25) .
Results
Most of the liver tumours observed in control CF-1 mice and in treatment groups up to the level of 5 p.p.m. dieldrin in the diet were classified as liver adenomas (Table I) . At higher dose levels, i.e., in the 10 and 20 p.p.m. treatment groups, -2/3 of the liver tumours were classified as carcinomas (Table I) . A substantial proportion of the animals exposed to 20 p.p.m. dieldrin died from acute intoxication within the first 3 months of experimentation. As with any non-liver tumour bearing animal, these early losses were classified as incidental deaths. The cumulative incidence of liver tumours (adenomas or carcinomas) as well as the cumulative incidence of liver carcinomas (only) is shown in Figure 1 . Both data sets showed an excellent fit to the log-normal distribution, and linear regressions were virtually parallel. The median liver tumour induction period was 1458 defined as the treatment interval up to a 50% incidence of liver tumours. Median liver carcinoma induction periods could not be established in any but two dose groups (10 and 20 p.p.m., respectively). Instead, the time interval up to a 10% incidence of liver carcinomas was used as an indicator of the carcinoma induction period (Table I) . The relationship between dieldrin dose and the acceleration of tumour formation was analysed with median liver tumour induction periods as well as with liver carcinoma induction periods. Both indicators of neoplastic response yielded similar results (see below).
Acceleration of liver tumour formation and dieldrin dose
The velocity of liver tumour formation and of liver carcinoma formation versus dieldrin dose is shown in Figure 2 . Tumourigenic response was found to be linearly related to dose:
The proportionality factor of dose (K), which is the tangent of an angle is defined as the ratio of the velocity of tumour development in control mice (1/T O ), and the background dose equivalent 
D o was found to be equipotent to a level of ~ 10 p.p.m. dieldrin in the diet (Figure 2 ). Equations (6) and (7) lead to: However, in the dieldrin study, the value of the exponent of time (n) equals 1, i.e., there is no time-associated acceleration of the neoplastic process in CF-1 mouse liver. The implication is that, in contrast to carcinogens (n > 1), the total tumourigenic dose (= D x x T x ) is constant across all doses. Dieldrin's actual contribution to the total tumourigenic dose is, however, dependent on the acceleration of liver tumourigenesis. Equation (10) can be modified to read as:
5 X X T x = D o X (T o -T x ) (13) In words, the shorter the median liver tumour induction period in dieldrin-treated mice, i.e., the higher the daily dieldrin dose level, the greater will have been dieldrin's contribution to the total tumourigenic dose (Table I) . This relationship is illustrated in Figure 4 .
Discussion
The analysis yielded a simple relationship to describe the doseresponse characteristics of enhanced liver tumour formation in dieldrin-treated CF-1 mice. The total tumourigenic dose, which is defined as the product of the sum of daily background and dieldrin dose (D x ) and the median liver tumour induction period (T x ), was shown to be constant across all doses.
The constancy of the product of concentration and time (needed to produce a specific effect) was first established for the action of a number of drugs by Clarke in a remarkable monograph published half a century ago (28) . A theoretical explanation for 'c.t. = constant' was provided by Druckrey and Kupfmuller in 1949 (18) .
These authors inferred that dose-response relationships are essentially determined by two processes (Table IT) , i.e., (i) the reversibility of binding to specific receptors in target cells, and (ii) the reversibility of the effect of receptor binding (pharmacological action or toxicity). The reversibility of any process is indi-cated by time constants (in this case, TR for binding to specific receptors, and T r for the effect of receptor binding) (Table II) .
When both of these time constants approach zero, i.e., when both processes are quickly reversible, the effect will be strictly dose-dependent ('Konzentrationsgift') (Table H) . However, when one of two processes is irreversible, the effect will depend on the dose as well as on the duration of treatment. This has now been demonstrated to be the case for the neoplastic response of mouse liver to dieldrin [equation (10)]. Presumably, the sustained but essentially reversible interaction of dieldrin with critical receptors in CF-1 mouse hepatocytes results in irreversible progression (read: acceleration) of an ongoing neoplastic process. Finally, Druckrey and Kupfmuller predicted that the irreversibility of both processes would lead to time-associated acceleration of the effect ('Verstarkerwirkung') ( Table H) . Such dose-response relationships were subsequently established for chemical carcinogens of different organotropy [equation (1) ing on the regulation of cell divisioin and cytodifferentiation ('expression of neoplastic potential') are likely to be irreversible processes. Thus, there would appear to be a fundamental difference in the nature of receptor binding between the non-genotoxic carcinogenesis enhancer dieldrin (29) (30) (31) and liver carcinogens, such a diethylnitrosamine, where n = 2.3 (19), or diethanolnitrosamine, where n = 4.7 (22) . It is interesting to note, in this context, that the dose-response relationship for dieldrin is very similar to that observed for 4-dimethylaminoazobenzene (4-DAB), where n = 1.1 (17, 19) . There is evidence to indicate that 4-DAB is a very poor initiator compared with diethylnitrosamine or diethanolnitrosamine (32). Druckrey's equation (1) holds for single-dose as well as chronic-exposure experiments with chemical carcinogens, and identical n-values (2.3) have been observed in single-dose experiments with N-nitroso-N-ethylurea (21) and in chronic-exposure experiments with diethylnitrosamine (19) . The 'initiation' of carcinogenesis is immediate, i.e., almost timeless in comparison with the latent period of tumours. The implication is that the second process, i.e., the expression of neoplastic potential, may well determine the kinetics of tumour development. Sharply delineated stages of functional development of hepatocytes, e.g., at birth and at the 'late suckling' period (33) , have been found to be associated with high susceptibility to a single dose of a liver carcinogen (34, 35) . Apparently, neoplastic potential is more readily expressed when, due to drastic changes in the animals' environment, initiated hepatocytes are committed to embark on a major process of functional development. Likewise, microsomal enzyme inducers, such as dieldrin, might enhance tumourigenesis by The results of a previous study (36) indicated that dieldrin is unlikely to exert its tumourigenic action by exacerbating the effect of a potent environmental carcinogen. No difference in liver tumour incidence was observed between CF-1 mice bred, reared and maintained on a semi-synthetic diet and filter-paper bedding, and those exposed to a conventional diet and sawdust bedding. Dieldrin was found to be equally tumourigenic in both environments (36) . These experimental data suggest that the origin of background tumours may be genetically-linked and transmitted from one generation to the next. If so, this neoplastic potential is only slowly expressed, under normal circumstances. The median liver tumour induction period in untreated control CF-1 mice (T o ) is 2.5 years, which exceeds the average lifespan of the animals by -6 months. The background dose (D o ) was found to be equipotent to a level of ~ 10 p.p.m. dieldrin in the diet.
It is conceivable that D o reflects a certain level of naturally occurring or endogenous substances, which express intrinsic neoplastic potential in mouse hepatocytes in the course of time. Equation (10) is consistent with the view that the effects of background tumorigens and dieldrin are additive, and that there is no threshold level for the tumour-promoting action of dieldrin. However, when the actual level of dieldrin in the diet is very low in comparison with the level of background tumorigens, dieldrin's contribution to liver tumour development is expected to be negligible. Accordingly, there may be a rationale for a practical 'no effect' level of carcinogenesis enhancers, such as dieldrin.
Dieldrin has been found to be non-tumourigenic in experimental species which are less susceptible to spontaneous development of liver tumours (37, 38) . The strain differences observed in the tumourigenic response of mouse liver to dieldrin (E.Thorpe, unpublished observations) and to phenobarbital (39) would also seem to be related to a different genetic predisposition to spontaneous tumourigenesis. Such observations are consistent with the view that pre-existing levels of tumour susceptibility in human populations could be critically important in defining virtually safe levels of tumour-promoting agents.
